NewsMeter
The $2.33 GAAP loss per share Sutro Biopharma reported came in $0.14 below analyst consensus. Revenue of $9.84 million missed estimates by $1.2 million, putting the implied consensus target at $11.04 million.
The quarter produced misses on both headline metrics.
The shortfall, reconciled | Metric | Reported | Implied consensus | Miss | |---|---|---|---| | GAAP EPS | -$2.33 | -$2.19 | -$0.14 | | Revenue | $9.84M | $11.04M | -$1.2M | Working backward from the stated shortfalls places consensus at -$2.19 on EPS.
Sutro Biopharma delivered -$2.33. On the top line, the implied estimate was $11.04 million; the actual figure was $9.84 million, short by $1.2 million. The math reconciles cleanly in both directions.
Keep reading